Your browser is no longer supported. Please, upgrade your browser.
Settings
TORC resTORbio, Inc. daily Stock Chart
TORC [NASD]
resTORbio, Inc.
Index- P/E- EPS (ttm)-1.45 Insider Own5.70% Shs Outstand27.93M Perf Week-26.14%
Market Cap180.71M Forward P/E- EPS next Y-3.17 Insider Trans- Shs Float7.42M Perf Month-19.43%
Income-37.60M PEG- EPS next Q-0.52 Inst Own43.90% Short Float36.49% Perf Quarter-32.74%
Sales- P/S- EPS this Y-18.10% Inst Trans0.71% Short Ratio25.84 Perf Half Y-53.98%
Book/sh3.71 P/B1.74 EPS next Y-24.80% ROA-30.50% Target Price32.00 Perf Year-55.99%
Cash/sh3.87 P/C1.67 EPS next 5Y29.30% ROE-32.60% 52W Range6.21 - 20.59 Perf YTD-24.94%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-68.58% Beta-
Dividend %- Quick Ratio19.20 Sales past 5Y- Gross Margin- 52W Low4.19% ATR0.73
Employees21 Current Ratio19.20 Sales Q/Q- Oper. Margin- RSI (14)34.11 Volatility15.53% 8.38%
OptionableNo Debt/Eq0.00 EPS Q/Q75.00% Profit Margin- Rel Volume2.91 Prev Close6.44
ShortableNo LT Debt/Eq0.00 EarningsMar 28 BMO Payout- Avg Volume104.79K Price6.47
Recom1.00 SMA20-21.03% SMA50-21.26% SMA200-38.98% Volume305,339 Change0.47%
Aug-01-18Downgrade Evercore ISI Outperform → In-line
Mar-22-19 10:02AM  resTORbio, Inc. Announces Closing Public Offering of Common Stock GlobeNewswire
Mar-19-19 07:32PM  resTORbio, Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire -22.87%
Mar-18-19 04:17PM  resTORbio, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
04:01PM  resTORbio Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
07:12AM  resTORbio Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Global Phase 3 Program for RTB101 GlobeNewswire
Feb-21-19 08:00AM  resTORbio to Present at 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-06-19 08:30AM  resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal Chemistry GlobeNewswire
Jan-31-19 04:30PM  resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition and Neurodegenerative Disease GlobeNewswire
Dec-19-18 08:00AM  resTORbio Appoints William Marshall, M.D., as Vice President of Medical Sciences GlobeNewswire
Nov-13-18 08:00AM  resTORbio Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-08-18 07:12AM  resTORbio Co-Founder and Chief Medical Officer Joan Mannick, M.D., to Present on TORC1 Inhibition at The Gerontological Society of America 2018 Annual Scientific Meeting GlobeNewswire
Nov-07-18 08:00AM  resTORbio to Present at Upcoming Investor Conferences in November GlobeNewswire
Nov-06-18 08:00AM  resTORbio Appoints Michael Grissinger to its Board of Directors GlobeNewswire
Oct-16-18 07:12AM  resTORbio Announces Additional RTB101 Phase 2b Data Demonstrating Decreased Incidence of Laboratory-Confirmed RTIs with Severe Symptoms, Total Infections and UTIs GlobeNewswire +10.46%
Sep-24-18 08:00AM  resTORbio to Present at 2018 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-18-18 08:00AM  resTORbio Appoints Meredith Manning as Chief Commercial Officer GlobeNewswire
Aug-29-18 08:00AM  resTORbio to Present at Wells Fargo 2018 Healthcare Conference GlobeNewswire
Aug-15-18 08:00AM  resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors GlobeNewswire
Aug-09-18 08:00AM  resTORbio Reports Second Quarter 2018 Financial Results GlobeNewswire -5.11%
Jul-31-18 09:53AM  ResTORbio (TORC) Continue to Surge Higher? Zacks
Jul-30-18 07:00AM  resTORbio to Present at the Canaccord Genuity 38th Annual Growth Conference GlobeNewswire
Jul-28-18 08:38AM  3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys? Motley Fool
Jul-25-18 12:18PM  Why resTORbio, Inc. Stock Skyrocketed Today Motley Fool +49.50%
08:36AM  ResTORbio's stocks rockets on positive trial results, just as post-IPO lock up expires MarketWatch
07:00AM  resTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101 GlobeNewswire
Jul-11-18 02:07PM  resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune Function and Decreased Infection Rates in People Aged 65 Years and Older GlobeNewswire +10.98%
Jun-12-18 08:00AM  resTORbio Announces Appointment of Kerry Russell, M.D., Ph.D., as Vice President of Clinical Development GlobeNewswire
Jun-01-18 08:00AM  resTORbio to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-22-18 04:30PM  resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition GlobeNewswire
May-10-18 04:01PM  resTORbio Reports First Quarter 2018 Financial Results GlobeNewswire
May-09-18 04:05PM  resTORbio to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire +12.44%
08:30AM  resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the Elderly GlobeNewswire
May-01-18 04:05PM  resTORbio to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire +7.33%
Mar-29-18 04:05PM  resTORbio Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire -9.28%
12:21PM  A Cambridge biotech is the worst-performing IPO so far this year nationally American City Business Journals
Mar-19-18 08:00AM  resTORbio Announces Formation of Clinical Advisory Board GlobeNewswire
Feb-20-18 04:26PM  Four Reasons Behind BofA's Bullish Restorbio Initiation Benzinga
08:00AM  resTORbio to Present at the 2018 RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-14-18 10:00AM  resTORbio, Inc. (Nasdaq: TORC) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Jan-30-18 04:01PM  resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jan-29-18 07:30AM  [$$] Biotech's Brisk March Into Public Markets The Wall Street Journal
resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibitor of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is an orally administered, TORC1 inhibitor, which completed Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as urinary tract infections, neurodegenerative diseases, and heart failure. The company was founded in 2016 and is headquartered in Boston, Massachusetts.